The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Tsar’kova A.V.

V.I. Krasnopolsky Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

Balan V.E.

M.F. Vladimirsky Moscow Regional Research Clinical Institute

Orazov M.R.

Patrice Lumumba Russian University of Friendship of Peoples

Tikhomirova E.V.

Moscow Financial and Industrial University �Synergy�

Orlova S.A.

V.I. Krasnopolsky Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

Zhuravel’ A.S.

V.I. Krasnopolsky Moscow Regional Research Institute of Obstetrics and Gynecology

Titchenko Yu.P.

V.I. Krasnopolsky Moscow Regional Research Institute of Obstetrics and Gynecology

«Metabolic health» and endothelial function in women with polycystic ovary syndrome

Authors:

Tsar’kova A.V., Balan V.E., Orazov M.R., Tikhomirova E.V., Orlova S.A., Zhuravel’ A.S., Titchenko Yu.P.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2025;25(5): 27‑34

DOI: 10.17116/rosakush20252505127

Read: 174 times

Buy for 300₽
Contact the author
Table of contents

«METABOLIC HEALTH» AND ENDOTHELIAL FUNCTION IN WOMEN WITH POLYCYSTIC OVARY SYNDROME
«METABOLIC HEALTH» AND ENDOTHELIAL FUNCTION IN WOMEN WITH POLYCYSTIC OVARY SYNDROME

To cite this article:

Tsar’kova AV, Balan VE, Orazov MR, Tikhomirova EV, Orlova SA, Zhuravel’ AS, Titchenko YuP. «Metabolic health» and endothelial function in women with polycystic ovary syndrome. Russian Bulletin of Obstetrician-Gynecologist. 2025;25(5):27‑34. (In Russ.)
https://doi.org/10.17116/rosakush20252505127

 
Подписка 2026 Российский вестник акушера-гинеколога (Russian Bulletin of Obstetrician-Gynecologist)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Morphofunctional and biochemical dete­rminants of endo­thelial function in patients with a new coro­navirus infe­ction COVID-19. Russian Journal of Preventive Medi­cine. 2024;(10):90-96
Changes in the lipid profile, stru­ctural and functional states of blood vessels in patients with lymphomas and cardiovascular toxic risks during the chemotherapy. Russian Journal of Preventive Medi­cine. 2024;(10):117-124
Oxidative stress in the pathogenesis of chro­nic headache. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):35-40
Features of como­rbidity pathology in young people. Russian Journal of Preventive Medi­cine. 2024;(11):63-69
The significance of exogenous nitrate and nitrite of plant origin for vascular health. Russian Journal of Preventive Medi­cine. 2024;(11):141-146
Alte­rations in the acti­vity of glutathione-dependent enzy­mes in erythrocytes of patients with acute pancreatitis of varying seve­rity. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):10-15
Modern view on the etiology of gallstone disease in children. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):59-68
Options for the surgical technique of lapa­roscopic sleeve gastrectomy for prevention and treatment of gastroesophageal reflux in patients with obesity. Endo­scopic Surgery. 2024;(6):57-68
Features of arte­rial blood flow velo­city characteristics in endo­thelial dysfunction. Russian Journal of Preventive Medi­cine. 2024;(12):100-106
Application of modern methods for acti­vation of brain functions in obese patients (literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6):54-61
Abstract:

Polycystic ovary syndrome (PCOS) is a widespread disease characterized by excessive androgen production, ovarian dysfunction and polycystic ovarian morphology, as well as multiple metabolic disorders. The interrelated effects of hyperandrogenism, obesity, and insulin resistance contribute to the development of hyperglycemia, dyslipidemia, adipokine imbalance, increased inflammatory activity, and the development of oxidative stress in women with PCOS. The listed factors have a detrimental effect on the state of the vascular wall, as a result of which the activity of its components, in particular, the endothelium, changes. Endothelial dysfunction is one of the first steps in the pathogenesis of cardiovascular diseases (CVD). Assessment of the risk of developing CVD and their prevention in the population of women with CVD are mandatory measures. Lifestyle change should be the first step in achieving this goal. In addition, it is necessary to keep in mind the available pharmaceutical support options.

Keywords:

polycystic ovary syndrome
endothelial dysfunction
obesity
dyslipidemia
adipokines
hyperandrogenism
chronic systemic inflammation
oxidative stress
therapeutic possibilities

Authors:

Tsar’kova A.V.

V.I. Krasnopolsky Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

Balan V.E.

M.F. Vladimirsky Moscow Regional Research Clinical Institute

Orazov M.R.

Patrice Lumumba Russian University of Friendship of Peoples

Tikhomirova E.V.

Moscow Financial and Industrial University �Synergy�

Orlova S.A.

V.I. Krasnopolsky Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

Zhuravel’ A.S.

V.I. Krasnopolsky Moscow Regional Research Institute of Obstetrics and Gynecology

Titchenko Yu.P.

V.I. Krasnopolsky Moscow Regional Research Institute of Obstetrics and Gynecology

Received:

23.10.2024

Accepted:

19.11.2024

Close metadata

References:

  1. Liao B, Qiao J, Pang Y. Central Regulation of PCOS: Abnormal neuronal-rReproductive-metabolic circuits in PCOS pathophysiology. Front Endocrinol (Lausanne). 2021;12:667422.
  2. Matsneva IA, Bakhtiyarov KR, Bogacheva NA, Golubenko EO, Pereverzina NO. System inflammation and insulin resistance in the polycystic ovarian syndrome. Health and Education Millennium. 2018;20:3. (In Russ.).
  3. Macut D, Bjekić-Macut J, Rahelić D, Doknić M. Insulin and the polycystic ovary syndrome. Diabetes Res Clin Pract. 2017;130:163-170. 
  4. Loverro G. Polycystic ovary syndrome and cardiovascular disease. Minerva Endocrinol. 2004;29:3:129-138. 
  5. Nayaker BS, Thomas S, Ramachandran S, Loganathan S, Sundari M, Mala K. Polycystic ovarian syndrome-associated cardiovascular complications: An overview of the association between the biochemical markers and potential strategies for their prevention and elimination. Diabetes Metab Syndr. 2017;11:Suppl 2:S841—S851.
  6. Phillips CM. Metabolically healthy obesity across the life course: epidemiology determinants, and implications. Ann N Y Acad Sci. 2017;1391:1:85-100. 
  7. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nature Reviews Microbiology. 2021;19:1:55-71. 
  8. Mel’nikova YuS, Makarova TP. Endothelial dysfunction as the key link of chronic diseases pathogenesis. Kazanskii meditsinskii zhurnal. 2015;96:4:659-665. (In Russ.). https://doi.org/10.17750/KMJ2015-659
  9. Ievleva KD, Danusevich IN, Suturina LV. Role of leptin and nuclear receptor PPARγ in PCOS pathogenesis. Problemy endokrinologii. 2020;66:6:74-80. (In Russ.). https://doi.org/10.14341/probl12620
  10. Smetnik VP. Sex hormones and adipose tissue. Ozhirenie i metabolism. 2007;4:3:17-22. (In Russ.).
  11. Rasin MS, Zhitnik VP. Systemic inflammation and insulin resistance in the pathogenesis of polycystic ovary syndrome. Akusherstvo i ginekologiya. 2015;8:26-32. (In Russ.).
  12. Abdusalamova AI, Bettikher OA, Rudenko KA, Belyaeva OA, Neimark AE, Zazerskaya IE. Adipokines and ghrelin role in regulation of ovarian function in obesity. Ozhirenie i metabolism. 2022;19:3:324-331. (In Russ.). https://doi.org/10.14341/omet12825
  13. Ryzhov YuR, Shpakov AO. Adiponectin as an endogenous regulator of the hypothalamicpituitary-gonadal axis. Translyatsionnaya meditsina. 2018;5:5:26-36. (In Russ.).
  14. Kovaleva YuV. Adipose tissue hormones and their role for female fertility and metabolic disorders. Arterial’naya gipertenziya. 2015;21:4:356-370. (In Russ.). https://doi.org/10.18705/1607-419X-2015-21-4-356-370
  15. Fouad Mansour M, Blanchette S, Pelletier M, Poirier D, Tchernof A. 17β-hydroxysteroid dehydrogenase type 2 activity, expression and cellular localization in abdominal adipose tissues from women. Clin Endocrinol (Oxf). 2023;98:2:229-237.  https://doi.org/10.1111/cen.14838
  16. Fouad Mansour M, Pelletier M, Boulet MM, Mayrand D, Brochu G, Lebel S, Poirier D, Fradette J, Cianflone K, Luu-The V, Tchernof A. Oxidative activity of 17β-hydroxysteroid dehydrogenase on testosterone in male abdominal adipose tissues and cellular localization of 17β-HSD type 2. Mol Cell Endocrinol. 2015;414:168-176.  https://doi.org/10.1016/j.mce.2015.06.016
  17. Jones MR, Mathur R, Cui J, Guo X, Azziz R, Goodarzi MO. Independent confirmation of association between metabolic phenotypes of polycystic ovary syndrome and variation in the type 6 17beta-hydroxysteroid dehydrogenase gene. J Clin Endocrinol Metab. 2009;94:12:5034-5038. https://doi.org/10.1210/jc.2009-0931
  18. Zaidieva YaZ, Balan VE, Tsar’kova AV. Relationship between adipocytes and androgens — the cause of comorbidities in women with polycystic ovary syndrome. Russian Bulletin of Obstetrician-Gynecologist. 2023;23:6:25-33. (In Russ.). https://doi.org/10.17116/rosakush20232306125
  19. Wu C, Wei K, Jiang Z. 5α-reductase activity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2017;15:1:21.  https://doi.org/10.1186/s12958-017-0242-9
  20. Pasquali R, Oriolo C. Obesity and androgens in women. Front Horm Res. 2019;53:120-134.  https://doi.org/10.1159/000494908
  21. Barber TM, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf). 2021;95:4:531-541.  https://doi.org/10.1111/cen.14421
  22. Rojas J, Chávez M, Olivar L, Rojas M, Morillo J, Mejías J, Calvo M, Bermúdez V. Polycystic ovary syndrome, insulin resistance, and obesity: Navigating the pathophysiologic labyrinth. Int J Reprod Med. 2014;2014:719050.
  23. Zaidieva YaZ, Balan VE. Polycystic ovarian syndrome: Clinical and diagnostic approaches. Moscow: Medical Information Agency. 2019; 17-18. 
  24. Moghetti P, Tosi F. Insulin resistance and PCOS: chicken or egg? J Endocrinol Invest. 2021;44:2:233-244. 
  25. Ray I, Mahata SK, De RK. Obesity: An Immunometabolic Perspective. Front Endocrinol (Lausanne). 2016;7:157.  https://doi.org/10.3389/fendo.2016.00157
  26. Sprung VS, Jones H, Pugh CJ, Aziz NF, Daousi C, Kemp GJ, Green DJ, Cable NT, Cuthbertson DJ. Endothelial dysfunction in hyperandrogenic polycystic ovary syndrome is not explained by either obesity or ectopic fat deposition. Clin Sci (Lond). 2014;126:1:67-74. 
  27. Shvarts VYa. Inflammation of the adipose tissue (part 4). Obesity: a new infectious disease? (a literature review). Problems of Endocrinology. 2011;57:5:63-71. (In Russ.).
  28. Rudnicka E, Suchta K, Grymowicz M, Calik-Ksepka A, Smolarczyk K, Duszewska AM, Smolarczyk R, Meczekalski B. Chronic Low Grade Inflammation in Pathogenesis of PCOS. Int J Mol Sci. 2021;22:7:3789. https://doi.org/10.3390/ijms22073789
  29. Shvarts VYa. Inflammation of the adipose tissue (part 7). Non-medicamental treatment. Problems of Endocrinology. 2012;58:2:62-70. (In Russ.).
  30. Shvarts VYa, Kolberg B. Inflammation of adipose tissue (part 5). The relationship with physiological insulin resistance. Problems of Endocrinology. 2011:57:6:64-70. (In Russ.).
  31. Igumnov IA, Sharifulin EM, Belen’kaia LV, Lazareva LM, Atalyan AV, Vil’son NI, Suturina LV. Chronic systemic inflammation in pathways of metabolic syndrome associated with hyperandrogenism (review). Patogenez. 2020;18:3:12-18. (In Russ.). https://doi.org/10.25557/2310-0435.2020.03.12-18
  32. Milyutina OV, Chicherina EN. The prognostic role of C-reactive protein in the development of the risk of cardiac events. Rossiiskii kardiologicheskii zhurnal. 2011;16:1:71-73. (In Russ.).
  33. Gorshunova NK, Rakhmanova OV. Oxidative stress and its varieties in the pathogenesis of arterial hypertension. Sovremennye problemy nauki i obrazovaniya. 2018;3:67. (In Russ.).
  34. Rudnicka E, Suchta K, Grymowicz M, Calik-Ksepka A, Smolarczyk K, Duszewska AM, Smolarczyk R, Meczekalski B. Chronic low grade inflammation in pathogenesis of PCOS. Int J Mol Sci. 2021;22:7:3789. https://doi.org/10.3390/ijms22073789
  35. Barvitenko N, Ashrafuzzaman M, Lawen A, Skverchinskaya E, Saldanha C, Manca A, Uras G, Aslam M, Pantaleo A. Endothelial cell plasma membrane biomechanics mediates effects of pro-inflammatory factors on endothelial mechanosensors: Vicious circle formation in atherogenic inflammation. Membranes (Basel). 2022;12:2:205.  https://doi.org/10.3390/membranes12020205
  36. Sergienko IV, Ansheles AA, Kukharchuk VV. Atherosclerosis and dyslipidemia: modern aspects of pathogenesis, diagnosis and treatment. Moscow: PatiSS. 2017;140. (In Russ.).
  37. Shvarts VYa. Adipose tissue inflammation. Part 1. Morphological and functional manifestations. Problemy endokrinologii. 2009;55:4:44-49. (In Russ.). https://doi.org/10.14341/probl200955444-49
  38. Sabuncu T, Vural H, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem. 2001;34:407-413. 
  39. Perovic Blagojevic IM, Vekic JZ, Macut DP, Ignjatovic SD, Miljkovic-Trailovic MM, Zeljkovic AR, Spasojevic-Kalimanovska VV, Bozic-Antic IB, Bjekic-Macut JD, Kastratovic-Kotlica BA, Andric ZG, Ilic DS, Kotur-Stevuljevic JM. Overweight and obesity in polycystic ovary syndrome: association with inflammation, oxidative stress and dyslipidaemia. Br J Nutr. 2022;128:4:604-612.  https://doi.org/10.1017/S0007114521003585
  40. Dinger Y, Akcay T, Erdem T, Ilker Saygili E, Gundogdu S. DNA damage, DNA susceptibility to oxidation and glutathione level in women with polycystic ovary syndrome. Scand J Clin Lab Invest. 2005;65:721-728. 
  41. Pingarrón Santofímia C, Poyo Torcal S, López Verdú H, Henríquez Linares A, Calvente Aguilar V, Terol Sánchez P, Martínez García MS, Lafuente González P. Evaluation of the efficacy of an antioxidant combination for the modulation of metabolic, endocrine, and clinical parameters in patients with polycystic ovary syndrome. Gynecol Endocrinol. 2023;39:1:2227277. https://doi.org/10.1080/09513590.2023.2227277
  42. Gonzalez F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:336-340. 
  43. González F, Considine RV, Abdelhadi OA, Acton AJ. Lipid-induced mononuclear cell cytokine secretion in the development of metabolic aberration and androgen excess in polycystic ovary syndrome. Hum Reprod. 2020;35:5:1168-1177. https://doi.org/10.1093/humrep/deaa056
  44. Guo F, Gong Z, Fernando T, Zhang L, Zhu X, Shi Y. The Lipid profiles in different characteristics of women with PCOS and the interaction between dyslipidemia and metabolic disorder states: A Retrospective study in chinese population. Front Endocrinol (Lausanne). 2022;13:892125. https://doi.org/10.3389/fendo.2022.892125
  45. Liu Q, Xie YJ, Qu LH, Zhang MX, Mo ZC. Dyslipidemia involvement in the development of polycystic ovary syndrome. Taiwan J Obstet Gynecol. 2019;58:4:447-453.  https://doi.org/10.1016/j.tjog.2019.05.003
  46. Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2011;95:3:1073-1079 e1-11. 
  47. Cree-Green M. Editoral commentary: Understanding cardiovascular disease risk in women with polycystic ovary syndrome. Trends Cardiovasc Med. 2020;30:7:405-406. 
  48. Karila D, Kerlan V, Christin-Maitre S. Androgenic steroid excess in women. Ann Endocrinol (Paris). 2024;85:2:142-149.  https://doi.org/10.1016/j.ando.2023.11.001
  49. Tchernof A, Brochu D, Maltais-Payette I, Mansour MF, Marchand GB, Carreau A-M, Kapeluto J . Androgens and the regulation of adiposity and body fat distribution in humans. Compr Physiol. 2018;8:4:1253-1290.
  50. Shvarts VYa. Inflammation of adipose tissue. Part 3. Pathogenetic role in the development of atherosclerosis. Problemy endokrinologii. 2009;55:6:40-45. (In Russ.). https://doi.org/10.14341/probl200955444-49
  51. Clinical guidelines of the Russian Ministry of Health: Polycystic ovary syndrom. 2021. (In Russ.).
  52. Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA, Norman RJ, Mousa A, Joham AE. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108:10:2447-2469. https://doi.org/10.1210/clinem/dgad463
  53. Kahn SE, Deanfield JE, Jeppesen OK, Emerson SS, Boesgaard TW, Colhoun HM, Kushner RF, Lingvay I, Burguera B, Gajos G, Horn DB, Hramiak IM, Jastreboff AM, Kokkinos A, Maeng M, Matos ALSA, Tinahones FJ, Lincoff AM, Ryan DH; SELECT Trial Investigators. Effect of semaglutide on regression and progression of glycemia in people with overweight or obesity but without diabetes in the SELECT trial. Diabetes Care. 2024;47:8:1350-1359. https://doi.org/10.2337/dc24-0491
  54. Bergmann NC, Davies MJ, Lingvay I, Knop FK. Semaglutide for the treatment of overweight and obesity: A review. Diabetes Obes Metab. 2023;25:1:18-35.  https://doi.org/10.1111/dom.14863
  55. Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG. The endothelial glycocalyx: Composition, functions, and visualization. Pflugers Arch Eur J Physiol. 2007;454:3:345-359. 
  56. Cao R-N, Tang L, Xia ZY, Xia R. Endothelial glycocalyx as a potential theriapeutic target in organ injuries. Chin Med J (Engl). Ovid Technologies (Wolters Kluwer Health). 2019;132:8:963-975. 
  57. Coccheri S. Biological and clinical effects of sulodexide in arterial disorders and diseases. Int Angiol. 2014;33:3:263-274. 
  58. Luk’yanova YuS, Pokrovskii MV. Basic pathophysiological and molecular mechanisms of chronic venous diseases and their pharmacological correction. Klinicheskaya farmakologiya i terapiya. 2019;28:3:52-61. (In Russ.). https://doi.org/10.32756/0869-5490-2019-3-52-61
  59. Lapina IA, Dobrokhotova YuE, Taranov VV, Proskurnikova DO, Sorokin YuA, Chirvon TG, Malakhova AA. Correction of endothelial dysfunction as a part of preconception preparation of patients with metabolic syndrome and polycystic ovary syndrome: multidisciplinary approach. Tromboz, gemostaz i reologiya. 2022;3:90-98. (In Russ.). https://doi.org/10.25555/THR.2022.3.1034
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.